PTX signs CAR-T agreement with Peter MacCallum
Filed with ASX · · 4 pages · English
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- March 2021 Quarterly Update and Appendix 4C
- PTX-200 AML Trial Progresses to Higher Dose
- December 2020 Quarterly Update and Appendix 4C
- PTX announces 3 next-gen CAR-T programs with OmniCAR
- Prescient Receives $1.03m R&D Tax Rebate
Later from Prescient Therapeutics
- Response to ASX Price Query
- PTX Completes CAR-T Manufacturing Milestone for OmniCAR
- PTX successful immunogenicity testing of OmniCAR
- PTX-100 trial advances following successful Phase 1b
- June 2021 Quarterly Activities and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics